MetaCap

DexCom (DXCM) vs Insulet (PODD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

DexCom (DXCM) has outperformed Insulet (PODD) over the past year, gaining 31.7% versus a loss of 59.8%. Over five years, DXCM leads with a -46.4% price change compared with -54.9% for PODD. DexCom is the larger company by market cap ($29.58 billion vs $9.24 billion), about 3.2 times the size, while Insulet is growing revenue faster (+30.7% vs +15.6%).

On valuation, Insulet trades at a lower forward P/E (16.8x vs 25.3x for DexCom). DexCom converts more of its revenue into profit, with a net margin of 17.9% versus 9.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DXCM+31.70%PODD-59.79%
+59%-4%-66%
Nov 21, 20251 yearNov 20, 2026
DXCM-50.52%PODD-55.76%
+20%-25%-70%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DXCM versus PODD key metrics
MetricDXCMPODD
Share price$79.32$133.17
Market cap$29.58B$9.24B
1-day change-1.08%-2.96%
YTD return+19.51%-53.15%
1-year return+31.70%-59.79%
5-year return-46.40%-54.92%
P/E ratio (TTM)31.2321.76
Forward P/E25.3016.83
EPS (TTM)$2.54$6.12
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$4.66B$2.71B
Revenue growth (YoY)+15.60%+30.73%
Net income (latest FY)$836.30M$247.10M
Gross margin60.10%71.63%
Operating margin19.56%17.50%
Net margin17.94%9.12%
52-week high$92.59$342.13
52-week low$56.72$126.40
Distance from 52-week high-14.33%-61.08%
Analyst consensusstrong_buybuy
Avg. price target upside+24.28%+33.60%
Average volume4.19M1.61M
Shares outstanding372.95M69.37M
Employees11,0005,400
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DexCom is about 3.2 times larger than Insulet by market value ($29.58B vs $9.24B).
  • DXCM has outperformed PODD by 91.5 percentage points over the past year.
  • DexCom trades at a higher earnings multiple (31.2x vs 21.8x trailing P/E).
  • DexCom is more profitable, keeping 17.9 cents of every revenue dollar as net income versus 9.1 cents for Insulet.
  • Insulet grew revenue faster in its latest fiscal year (+30.73% vs +15.60%).

About DexCom

DXCM stock →

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application.

Health Care · Medical/Dental Instruments · 11,000 employees

About Insulet

PODD stock →

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System.

Health Care · Medical/Dental Instruments · 5,400 employees

DXCM vs PODD FAQ

Which is bigger, DexCom or Insulet?

DexCom (DXCM) is larger, with a market capitalization of $29.58B compared with $9.24B for Insulet (PODD).

Which stock has performed better over the past year, DXCM or PODD?

DXCM returned +31.70% over the past 12 months, compared with -59.79% for PODD (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, DXCM or PODD?

PODD has the lower trailing P/E at 21.8, versus 31.2 for DXCM. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are DexCom and Insulet in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons